

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Rasappa G. Arumugham et al.

Application No.: 10/583,503

Filed: November 17, 2006

For: A-BETA IMMUNOGENIC
PEPTIDE CARRIER CONJUGATES
AND METHODS OF PRODUCING
SAME

Customer No.: 00826

Confirmation No.: 4013

Examiner: Satyanarayan R. Gubibande

Art Unit: 1654

**SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT UNDER
37 CFR §1.97 and §1.98**

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Commissioner:

The references cited on attached forms PTO/SB/08A and PTO/SB/08B are being called to the attention of the Examiner. In compliance with the requirements of 37 CFR §1.98(a)(2), copies of the references are submitted herewith.

It is respectfully requested that the cited references be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

As provided for by 37 CFR §1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.

STATEMENT UNDER 37 C.F.R § 1.97(e)(1)


The undersigned hereby states that each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement.

STATEMENT UNDER 37 C.F.R § 1.704(d)

The undersigned hereby states that each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart application and that this communication was not received by any individual designated in § 1.56(c) more than thirty days prior to the filing of this Information Disclosure Statement.

This IDS is being filed before the issuance of a Notice of Allowance.

Please charge the IDS fee of \$180 to Deposit Account No. 16-0605. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,

Lance A. Termes
Reg. No. 43,184

Customer No. 00826
ALSTON & BIRD LLP
Bank of America Plaza
101 South Tryon Street, Suite 4000
Charlotte, NC 28280-4000
Tel: Silicon Valley Office (650) 838-2000
Fax: Charlotte Office (704) 444-1111
LAT/jcf
LEGAL02/32764244v1